SYMBIOTEC SYMBIOTEC Q1 FY27 results (Apr–Jun 2026) and concall
In its first call as a listed company, Symbiotec posted consolidated revenue of ₹218 crores (+7% YoY), almost all from its steroid and hormone API business (₹215 crores, +6%), where API EBITDA grew 9% to ₹66 crores. Consolidated EBITDA of ₹45 crores and PAT of about ₹14 crores were held down by ₹34 crores of opex and depreciation from the new biotech CDMO and complex injectables businesses, which have not started earning revenue. Management guided FY27 revenue growth of about 20% and EBITDA growth of about 25% (±5%), with H2 driven by milestone payments and first biotech CDMO revenue in Q4. It
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q1 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 203 | 245 | 7 |
| EBITDA | 58 | 62 | 45 |
| Net profit | 30 | 28 | 14 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
